Black Diamond Therapeutics (BDTX) Consolidated Net Income: 2018-2021
Historic Consolidated Net Income for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$25.5 million.
- Black Diamond Therapeutics' Consolidated Net Income fell 16.25% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$111.6 million, marking a year-over-year decrease of 68.00%. This contributed to the annual value of -$123.4 million for FY2021, which is 88.32% down from last year.
- Per Black Diamond Therapeutics' latest filing, its Consolidated Net Income stood at -$25.5 million for Q4 2021, which was up 26.30% from -$34.6 million recorded in Q3 2021.
- Over the past 5 years, Black Diamond Therapeutics' Consolidated Net Income peaked at -$3.0 million during Q4 2018, and registered a low of -$34.6 million during Q3 2021.
- For the 3-year period, Black Diamond Therapeutics' Consolidated Net Income averaged around -$16.8 million, with its median value being -$14.3 million (2020).
- Data for Black Diamond Therapeutics' Consolidated Net Income shows a maximum YoY plummeted of 235.30% (in 2020) over the last 5 years.
- Black Diamond Therapeutics' Consolidated Net Income (Quarterly) stood at -$3.0 million in 2018, then slumped by 225.15% to -$9.9 million in 2019, then crashed by 121.42% to -$21.9 million in 2020, then decreased by 16.25% to -$25.5 million in 2021.
- Its Consolidated Net Income was -$25.5 million in Q4 2021, compared to -$34.6 million in Q3 2021 and -$29.6 million in Q2 2021.